Net revenue for the three months ended September 30, 2024, was $82.6 million, compared to $3.5 million for the same period in 2023, reflecting an increase of $79.1 million. This increase was driven ...
Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo” or the "Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback